Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is anticipated to announce its earnings results on Monday, March 24th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Quince Therapeutics Stock Performance

Quince Therapeutics stock opened at $1.38 on Friday. The company has a 50 day moving average price of $1.50 and a 200-day moving average price of $1.42. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The company has a market capitalization of $60.72 million, a PE ratio of -1.11 and a beta of 0.71.

Analyst Ratings Changes

Several analysts have recently weighed in on QNCX shares. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Brookline Capital Management started coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Quince Therapeutics presently has a consensus rating of “Buy” and an average target price of $9.50.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.